Background and objective: We evaluated the risk of hepatotoxicity associated to endothelin receptor antagonists.
Patients and method: Systematic searches in PubMed/MEDLINE, the Cochrane Library as well as regulatory agencies websites were performed. Randomized controlled trials in patients receiving endothelin receptor antagonists (bosentan, sitaxentan or ambrisentan) in at least one treatment group were included. Prior to data extraction, definitions of hepatotoxicity were established. Effect sizes with 95% confidence intervals were calculated using random effects models. Heterogeneity was analysed using Cochran's Q and I(2) tests. Publication bias was assessed using Egger's method and funnel plots were generated.
Results: Twenty-one trials met the inclusion criteria (3,644 patients). Bosentan was the evaluated drug in 1,689 (74%) patients who received endothelin receptor antagonists. Compared with controls, relative risk for any hepatic adverse reaction was 2.92 (1.85-4.62; I(2)=30.6%). When hepatotoxicity was defined as elevations of liver alanine or aspartate aminotransferases equal or greater than 3 times the upper limit of normal, relative risk was 2.98 (1.69-5.25; I(2) = 40.9%). No evidence of publication bias was found (Egger's method: p = 0.68).
Conclusions: Our results suggest an increased risk of hepatotoxicity in patients receiving endothelin receptor antagonists. Given the limited data available for endothelin receptor antagonists other than bosentan, it is not possible to draw firm conclusions about the individual risk associated for the remaining endothelin receptor antagonists.
Keywords: Ambrisentan; Ambrisentán; Bosentan; Bosentán; Daño hepático; Ensayo clínico aleatorizado y controlado; Hepatic event; Hepatotoxicidad; Hepatotoxicity; Liver injury; Meta-analysis; Metaanálisis; Randomized controlled trial; Reacción hepática; Sitaxentan; Sitaxentán; Sitaxsentan; Sitaxsentán.
Copyright © 2012 Elsevier España, S.L. All rights reserved.